{"id":2752,"date":"2020-05-14T00:00:00","date_gmt":"2021-03-18T02:35:12","guid":{"rendered":"https:\/\/www.eisai.com.cn\/?p=2752"},"modified":"2021-03-18T10:35:12","modified_gmt":"2021-03-18T02:35:12","slug":"eisai-to-present-data-on-oncology-pipeline-and-products-at-asco-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.eisai.com.cn\/en\/2020\/05\/14\/eisai-to-present-data-on-oncology-pipeline-and-products-at-asco-annual-meeting\/","title":{"rendered":"EISAI TO PRESENT DATA ON ONCOLOGY PIPELINE AND PRODUCTS AT ASCO ANNUAL MEETING"},"content":{"rendered":"<p>Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \u201cEisai\u201d) announced today that presentations on a series of abstracts regarding its in-house discovered lenvatinib mesylate (multikinase inhibitor, product name: LENVIMA<sup>\u00ae<\/sup>, \u201clenvatinib\u201d) and eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: HALAVEN<sup>\u00ae<\/sup>, \u201ceribulin\u201d) will be given at the American Society of Clinical Oncology (ASCO20 Virtual Scientific Program*), from May 29 to 31, 2020.<br \/>\n* Presentation materials will be made available on demand via ASCO\u2019s website at 8:00 AM on May 29<sup>th\u00a0<\/sup>(ET).<\/p>\n<p>At this year\u2019s meeting, the final results of two studies will be presented on the combination therapy of lenvatinib with the anti-PD-1 antibody KEYTRUDA<sup>\u00ae<\/sup>\u00a0(generic name: pembrolizumab, \u201cpembrolizumab\u201d) from Merck &amp; Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada). One is the oral presentation of the metastatic renal cell carcinoma cohort (Abstract number: 5008) of Study 111 \/ KEYNOTE-146, and the other is the poster discussion presentation of the first-line therapy for unresectable hepatocellular carcinoma (Abstract number: 4519) in Study 116 \/ KEYNOTE-524**.<br \/>\n**This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds and investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.<\/p>\n<p>In March 2018, Eisai and Merck &amp; Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.<\/p>\n<p>Eisai positions oncology as a key franchise area and aims to create innovative drugs that act towards\u00a0<i>curing cancer<\/i>. Eisai will continue to create innovation in the development of new drugs based on cutting-edge cancer research, and aims to make continuous efforts to meet the diversified needs of and increase the benefits provided to patients with cancer, their families, and healthcare professionals.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \u201cEisai\u201d) announced today that presentations on a series of abstracts regarding its in-house discovered lenvatinib mesylate (multikinase inhibitor, product name: LENVIMA\u00ae, \u201clenvatinib\u201d) and eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: HALAVEN\u00ae, \u201ceribulin\u201d) will be given at the American Society of Clinical Oncology (ASCO20 Virtual Scientific Program*), from May 29 to 31, 2020.<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[28],"tags":[],"class_list":["post-2752","post","type-post","status-publish","format-standard","hentry","category-news-en"],"_links":{"self":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts\/2752"}],"collection":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/comments?post=2752"}],"version-history":[{"count":2,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts\/2752\/revisions"}],"predecessor-version":[{"id":2754,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/posts\/2752\/revisions\/2754"}],"wp:attachment":[{"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/media?parent=2752"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/categories?post=2752"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.eisai.com.cn\/wp-json\/wp\/v2\/tags?post=2752"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}